Phase II trial of high-dose cisplatin in patients with malignant mesothelioma

D. M. Mintzer; D. Kelsen; D. Frimmer; R. Heelan; R. Gralla

Phase II trial of high-dose cisplatin in patients with malignant mesothelioma

D. M. Mintzer, D. Kelsen, D. Frimmer, R. Heelan, R. Gralla

Research output: Contribution to journal › Article › peer-review

Abstract

Twenty-five patients with advanced malignant mesothelioma were treated in a phase II trial with high-dose cisplatin (DDP). All patients had measurable or evaluable disease. Seven patients had received prior chemotherapy. DDP (120 mg/m²) with mannitol and prehydration was given every 4 weeks for two doses and then every 6 weeks. Of 24 patients evaluable for response, three had partial responses (3, 3+, and 9 months; response rate, 13%; 95% confidence limits, 4%-31%) and one had minor response. All responses occurred in previously untreated patients. High-dose DDP has modest activity in malignant mesothelioma.

Original language	English (US)
Pages (from-to)	711-712
Number of pages	2
Journal	Cancer Treatment Reports
Volume	69
Issue number	6
State	Published - 1985
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{054a0b46b47e44ecb486a81835bbf736,

title = "Phase II trial of high-dose cisplatin in patients with malignant mesothelioma",

abstract = "Twenty-five patients with advanced malignant mesothelioma were treated in a phase II trial with high-dose cisplatin (DDP). All patients had measurable or evaluable disease. Seven patients had received prior chemotherapy. DDP (120 mg/m2) with mannitol and prehydration was given every 4 weeks for two doses and then every 6 weeks. Of 24 patients evaluable for response, three had partial responses (3, 3+, and 9 months; response rate, 13%; 95% confidence limits, 4%-31%) and one had minor response. All responses occurred in previously untreated patients. High-dose DDP has modest activity in malignant mesothelioma.",

author = "Mintzer, {D. M.} and D. Kelsen and D. Frimmer and R. Heelan and R. Gralla",

year = "1985",

language = "English (US)",

volume = "69",

pages = "711--712",

journal = "Cancer Treatment Reports",

issn = "0361-5960",

publisher = "Oxford University Press",

number = "6",

}

TY - JOUR

T1 - Phase II trial of high-dose cisplatin in patients with malignant mesothelioma

AU - Mintzer, D. M.

AU - Kelsen, D.

AU - Frimmer, D.

AU - Heelan, R.

AU - Gralla, R.

PY - 1985

Y1 - 1985

N2 - Twenty-five patients with advanced malignant mesothelioma were treated in a phase II trial with high-dose cisplatin (DDP). All patients had measurable or evaluable disease. Seven patients had received prior chemotherapy. DDP (120 mg/m2) with mannitol and prehydration was given every 4 weeks for two doses and then every 6 weeks. Of 24 patients evaluable for response, three had partial responses (3, 3+, and 9 months; response rate, 13%; 95% confidence limits, 4%-31%) and one had minor response. All responses occurred in previously untreated patients. High-dose DDP has modest activity in malignant mesothelioma.

AB - Twenty-five patients with advanced malignant mesothelioma were treated in a phase II trial with high-dose cisplatin (DDP). All patients had measurable or evaluable disease. Seven patients had received prior chemotherapy. DDP (120 mg/m2) with mannitol and prehydration was given every 4 weeks for two doses and then every 6 weeks. Of 24 patients evaluable for response, three had partial responses (3, 3+, and 9 months; response rate, 13%; 95% confidence limits, 4%-31%) and one had minor response. All responses occurred in previously untreated patients. High-dose DDP has modest activity in malignant mesothelioma.

UR - http://www.scopus.com/inward/record.url?scp=0021885946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021885946&partnerID=8YFLogxK

M3 - Article

C2 - 4040424

AN - SCOPUS:0021885946

SN - 0361-5960

VL - 69

SP - 711

EP - 712

JO - Cancer Treatment Reports

JF - Cancer Treatment Reports

IS - 6

ER -

Phase II trial of high-dose cisplatin in patients with malignant mesothelioma

Abstract

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this